While not yet validated, ctDNA is being used by clinical experts as a de-escalation tool to provide confidence when stopping long-term maintenance therapies like PARP inhibitors. This novel application focuses on reducing treatment burden rather than solely detecting disease progression.

An expert oncologist advises against ordering ctDNA tests that merely provide a "good or a bad feeling" about prognosis. The most valuable use is when a positive or negative result clearly dictates a clinical action, such as when to stop or restart adjuvant therapy.

While ctDNA can detect molecular relapse 3-5 months before radiographic progression, experts argue this lead time is too short and doesn't sufficiently alter management to justify routine use outside of trials. The lack of superior subsequent therapies currently limits its clinical actionability and value.

A positive ctDNA test indicating minimal residual disease is strongly linked to recurrence. This expert argues clinicians have an obligation to act on this information, even without definitive guidelines. Framing inaction as unacceptable challenges the passive "wait-and-see" approach.

While patients increasingly ask about ctDNA, clinicians are hesitant to use it for treatment decisions in ovarian cancer management. A rising ctDNA level may prompt more vigilant surveillance but does not yet trigger treatment initiation, as its correlation with survival outcomes is unproven.

While promising, current ctDNA technology is not robust enough to justify stopping effective neoadjuvant systemic therapy in bladder cancer, even if a patient becomes ctDNA negative. Experts argue against using it to de-escalate treatment outside of a clinical trial due to the risk of undertreating a lethal disease.

Despite acknowledging that a one-size-fits-all treatment duration is suboptimal, the expert consensus is to follow the study protocol. This conservative, evidence-based approach prevails due to the absence of validated biomarkers, like ctDNA, to safely guide treatment de-escalation for individual patients.

Oncologists are more comfortable using a positive ctDNA test to escalate care (e.g., recommend chemo for a low-risk Stage II patient). However, they are more hesitant to use a negative test to de-escalate or withhold standard chemo for higher-risk patients, pending more definitive trial data.

Post-treatment ctDNA positivity is a powerful predictor of high recurrence risk in gastric cancer patients. However, this advanced diagnostic knowledge creates a clinical dilemma, as there is no evidence-based consensus on how to act on the results, forcing clinicians to make treatment decisions without supporting data.